NCT06129422View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Pancreatic Cancer
Interventions
DRUG

NMK89

Route of administration: intravenous infusion

Trial Locations (3)

33612

Moffitt Cancer Center, Tampa

49503

BAMF Health, Grand Rapids

98109

Fred Hutchinson Cancer Center, Seattle

All Listed Sponsors
lead

Nihon Medi-Physics Co., Ltd.

INDUSTRY

NCT06129422 - Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer | Biotech Hunter | Biotech Hunter